Genentech Rituxan Aggressive NHL sBLA Will Include Conflicting Survival Data
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Genentech’s upcoming Rituxan submission for use in aggressive non-Hodgkin’s lymphoma will likely include trials with conflicting survival data.